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3Abstract
Objective: To evaluate the cost-effectiveness of neurothrombectomy with a stent retriever
(Solitaire* Revascularization Device) in treating acute ischemic stroke patients from the UK
healthcare provider perspective.
Methods: A Markov model was developed to simulate health outcomes and costs of two
therapies over a lifetime time horizon: stent-retriever thrombectomy in combination with
intravenous tissue-type plasminogen activator (IV t-PA), and IV t-PA alone. The model
incorporated an acute phase (0-90 days) and a rest of life phase (90+ days). Health states
were defined by the modified Rankin Scale score. During the rest of life phase, patients
remained in the same health state until a recurrent stroke or death. Clinical effectiveness and
safety data were taken from the SWIFT PRIME study. Resource use and health state utilities
were informed by published data.
Results: Combined stent-retriever thrombectomy and IV t-PA led to improved quality of life
and increased life expectancy compared to IV t-PA alone. The higher treatment costs
associated with the use of stent-retriever thrombectomy were offset by long-term cost savings
due to improved patient health status, leading to overall cost savings of £33,190 per patient
and a net benefit of £79,402. Deterministic and probabilistic sensitivity analyses
demonstrated that the results were robust to a wide range of parameter inputs.
Limitations: The acute and long-term costs resource use data were taken from a study based
on a patient population that was older and may have had additional comorbidities than the
SWIFT PRIME population resulting in costs that may not be representative of the cohort
within our model. In addition, the estimates may not reflect stroke care today as no current
evidence is available; however, the cost estimates were deemed reasonable by clinical
opinion.
4Conclusions: Combined stent-retriever neurothrombectomy and IV t-PA is a cost-effective
treatment for acute ischemic stroke compared with IV t-PA alone.
*Solitaire Revascularization Device is a registered trademark of Medtronic, Irvine, CA, USA
5Introduction
Stroke is a major cause of morbidity and long-term disability both in the United Kingdom
(UK) and worldwide. In the UK, approximately 150,000 strokes occur each year with an
estimate of more than 300,000 people living with stroke-related permanent disability.1,2
Stroke is also a significant cause of mortality in the UK, accounting for around 53,000 deaths
each year, or 9% of all deaths.3 Due to the UK’s aging population and increasing prevalence
of obesity, the incidence of stroke is set to increase further.4-6 The substantial health burden
of stroke is matched by a substantial economic burden as it results in sizable treatment costs
often associated with extensive hospitalisation and long-term ongoing care costs after
discharge from hospital due to stroke-related disability. The estimated cost of stroke in
England is approximately £8.9 billion per year, of which 50% are direct costs to the National
Health Service (NHS).7
Stroke care in the UK has seen significant reorganisation over the last decade with
care being increasingly delivered in specialist units, as they have achieved better recovery
from stroke.8,9 Currently, intravenous tissue plasminogen activator (IV t-PA) represents the
best available pharmacological treatment for acute ischemic stroke in the UK as established
by the National Institute for Health Care Excellence (NICE) single technology appraisal
(STA); therefore, it is the comparator therapy in the present economic evaluation. Recently,
endovascular treatment with stent retrievers has emerged as an important treatment option for
acute ischemic stroke patients with large vessel occlusion.13-17
While there are clinical data supporting stent-retriever thrombectomy, limited
economic evidence to support the routine use of stent retrievers in current stroke care exists.
One recent study on the cost-effectiveness of intra-arterial therapy in the United States (US)
suggested that intra-arterial treatment was a cost-effective treatment with an estimated
incremental cost-effectiveness ratio (ICER) of $14,137 (£10,011) per quality-adjusted life
6year gained (QALY).18 This analysis was based on data from the MR CLEAN trial, which
includes use of various intra-arterial interventions including stent retrievers,
thromboaspiration, and intra-arterial thombolysis. The aim of our study was to evaluate from
the UK healthcare provider perspective the cost-effectiveness of combined stent-retriever
(Solitaire* Revascularization Device) thrombectomy and IV t-PA compared to IV t-PA alone
as a treatment for acute ischemic stroke by leveraging the recently available data from the
Solitaire With the Intention For Thrombectomy as Primary Endovascular Treatment for
Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial.13
Methods
Model Overview
The model was designed in collaboration between stroke clinicians and experts in health care
economics and was based on a pragmatic review of previous decision analytical models
developed in stroke care. On consideration of the available data, a model structure similar in
design to that used in the NICE single technology appraisal of alteplase was developed.19
Clinical efficacy and safety data used in the analysis was sourced from the SWIFT PRIME
study - a multicenter randomized clinical trial conducted in the United States and Europe on
patients suffering from large vessel anterior circulation occlusions (ClinicalTrials.gov
Identifier: NCT01657461).13 The study compared stent-retriever thrombectomy in
combination with IV t-PA, with IV t-PA alone. A targeted literature search was undertaken to
populate the model inputs that were not provided by SWIFT PRIME13 trial data, such as the
costs related to acute ischemic stroke and the recurrence of stroke.
This economic analysis was conducted assuming a UK healthcare provider
perspective and a lifetime time horizon was considered. Outcomes were also evaluated at
after one, two, and five years. All costs were inflated to 2013/14 prices using the Hospital and
7Community Services Inflation Index.20 Health outcomes and future costs were discounted at
3.5% following NICE recommendations.21 The model was developed and run inMicrosoft
Excel 2010.
Patients
Patients in the model were based on the population in the SWIFT PRIME13 trial. Institutional
Review Boards/Ethics Committees at sites approved the trial and all subjects provided
informed consent. Briefly, patients were eligible for enrollment into the trial if they had
confirmed occlusions in the proximal anterior intracranial circulation and an absence of large
ischemic-core lesions. Moreover, patients in the combined stent-retriever and IV t-PA arm
had to undergo mechanical thrombectomy within 6 hours of symptom onset. For the present
analysis, starting age in the base case and scenario analysis was 66, the mean age of the
SWIFT PRIME13 trial population. There was no participating center located in the UK.
Model Structure
A Markov decision model was used to simulate and predict long-term health outcomes and
costs of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA
alone. A diagrammatical depiction of the model structure is presented in Figure 1. In the base
case, the model structure used two distinct phases to model patient outcomes, including an
acute phase and a rest of life phase. The acute phase modelled patients from stroke onset to
90 days (Table 1), in which they were assumed to receive treatment, and a rest of life phase
spanning from 91 days to the end of the patients’ lives. A total of seven health states were
used in the model based on the modified Rankin Scale (mRS). The scale ranges from 0 to 6
and is defined as; mRS 0 – no symptoms, mRS 1 – no clinically significant disability, mRS 2
– slight disability, mRS 3 – moderate disability, mRS 4 – moderately severe disability, mRS
85 – severe disability and mRS 6 is dead.22 Death was the only absorbing state within the
model. All treatment effects were assumed to occur within the acute phase and a patient was
assigned an mRS score at 90 days and at 7 days to allow for half cycle correction. During the
acute phase, the patient was at risk of two different adverse events; symptomatic hemorrhage
and vasospasm. Experiencing an adverse event incurred additional costs, however no
disutility was applied as it was assumed that quality of life was reflected in the 90 day mRS.
The vasospasms that occurred in SWIFT PRIME were intra-procedural and were brief and
asymptomatic. Because of this, it is unlikely that the vasospasms in SWIFT PRIME will have
resulted in any additional costs; however, a conservative approach was taken and the costs
related to the injection to Nimotop® were included within the model. For similar reasons, it
was also assumed that a patient was at no risk of recurrent stroke in this 90 day period.
Effectiveness data and risk of adverse events were populated from the SWIFT PRIME13 trial.
In the base case, the second phase of the model was made up of two cycle lengths.
The first cycle length was 275 days, bringing a patient’s time after stroke to one year. After
this, the cycle length became from one year onwards. In the rest of life phase of the model, a
patient remained in the same mRS as at 90 days until either a recurrent stroke or death.
Recurrent stroke probabilities were taken from Mohan and coworkers23 who used a statistical
model to demonstrate time trends in risk of recurrent stroke to predict future trends (Table 2).
Cumulative risk at one year and at five years after first stroke were reported and these were
used as the risk in the first cycle of the rest of life phase (90 days to one year) and the annual
cycles after the first year, respectively, within our model. These risks were adjusted to reflect
the two different cycle lengths within the model. Risk of recurrent stroke was the same across
all mRS scores and it was assumed that a patient could experience a maximum of one
recurrent stroke per cycle.
9If a patient experienced a recurrent stroke, the patient re-entered the model from the
start with restricted movement. That is, a patient with a recurrent stroke was only able to have
an mRS score equal to or greater than their mRS before that recurrent stroke. The patient then
continued through the model as previously described.
In a scenario analysis, a further stage was added to the model to create a three stage
structure. These three phases were the acute phase from 0 to 90 days, a rehabilitation phase
from 91 days to one year and a rest of life phase from one year onwards. In the rehabilitation
phase, patients could either remain in the same health state (maintain their 90 day mRS
score), improve by one health state or deteriorate by one health state (Table 3). The
rehabilitation phase was included based on evidence that a patient’s recovery from stroke is
not complete at 90 days. Therefore, patients can often have different mRS scores at one year
follow-up due to rehabilitation and other factors.24-26 Within the rehabilitation phase, as in the
rest of life phase, a patient was at risk of recurrent stroke and could only experience one
recurrent stroke in this phase. The rehabilitation phase was not included in the base case due
to a lack of reliable data on patients’ likely progression through this phase. It was instead
included in a scenario analysis to explore the potential impact of post 90-day improvement in
mRS score on estimated cost-effectiveness.
Costs and Resource Use
Costs and resource use in the model are presented in Tables 4 and 5. Costs can be broken
down into treatment costs, costs in the acute phase and costs in the rest of life phase. The
overall costs included device and drug costs, costs of administering treatment (e.g. staff and
overhead costs), management of adverse events, hospitalization costs, and long-term care
costs. Treatment and device costs for the stent retriever were provided by Medtronic and the
resource use (e.g. staff and theatre time for stent-retriever thrombectomy) was elicited from
clinicians with costs sourced from Personal Social Services Research Unit (PSSRU20), Unit
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Costs of Health & Social Care. Costs and resource use associated with IV t-PA were derived
from the Single Technology Appraisal for alteplase (TA122)19,27,28 and PSSRU, and were
updated to 2014 figures where appropriate.29 Long-term costs were based on data from the
OXVASC study30 and additional nursing and residential care costs, also reported in the study,
were included to reflect personal social services costs as required by the NICE reference
case.31 Data was only available for three levels of post stroke disability; mRS 0 to 2, mRS 3
to 4 and mRS 5. Based on the consensus of three clinical experts, a weighting on the three
levels was applied in order to calculate individual costs by mRS. The net monetary benefit
was calculated by multiplying the incremental total QALYs by the willingness to pay
threshold of £20,000. The incremental total costs were then subtracted from this. This allows
for the additional QALYs to be valued in monetary terms and the overall monetary benefit
estimated by taking into account the extra costs/cost-savings associated with the intervention.
Quality of Life
Utilities were assigned to each health state and were based on patients in the Oxford Vascular
Study (OXVASC), UK.32 Utility values for the health states ranged from 0.935 to -0.054,
where an mRS score of 5 resulted in a negative utility, indicating that living with mRS 5 is
worse than death. Table 6 presents the health state utility values used in the model.
Mortality
Age-specific other-cause mortality was applied to patients in the rest of life phase of the
model (one year+) to model deaths unrelated to stroke. Mortality data from the 2011-2013
Office of National Statistics Life Tables were used.33 Relative risks of dying by mRS (values
reported in Table 2) were also applied to other-cause mortality in this phase and were taken
from Slot et al 2009.34 It was assumed that mRS 0 could be taken as baseline, and that a
patient with mRS 0 had the same risk of dying as anyone within the same demographic that
had not experienced a stroke.
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Model Outcomes
A number of economic outcomes were calculated as part of the analysis. The primary
outcome of the analysis is the incremental cost-effectiveness ratio (ICER). The ICER was
calculated by dividing the incremental costs by the incremental QALYs. Net monetary
benefit (NMB) was calculated using a £20,000 threshold, using recommendations of the
1,&(UHIHUHQFHFDVH10% ¨4$/<V[Ȝ¨&RVWVZKHUH¨4$/<VLVWKHGLIIHUHQFHLQ
4$/<V¨&RVWVLVWKHGLIIHUHQFHLQFRVWVDQGȜLVWKHWKUHVKROGYDOXHDGRSWHG31 Costs and
QALYs were evaluated over the patient lifetime, and at one, two, and five years. In addition
to these generic measures of cost-effectiveness, a number of disease specific measures of
cost-effectiveness were calculated, specifically the average cost per mRS score avoided, the
cost per additional independent patient (mRS<3) and the cost saved (by mRS) over a
patient’s lifetime due to improvement by one mRS.
A number of deterministic sensitivity analyses were performed to explore uncertainty
around input parameter values. Probabilistic sensitivity analysis was also undertaken to assess
overall uncertainty in the model. This was implemented by assigning a probability
distribution to key parameters to represent the uncertainty around its mean value; one value
was sampled from each distribution and the results calculated using these sampled inputs.
This process was repeated 1,000 times to generate repeated estimates of the costs and QALYs
associated with each intervention. mRS at 90 days was modelled using a Dirichlet
distribution.35 Cost inputs were varied according to a gamma distribution, and relative risks
of mortality were varied according to a lognormal distribution. Utilities were varied
according to a beta distribution, with alpha and beta estimated from the mean and SE values.
The internal validity of the model was checked by a health economist of York Health
Economist Consortium not involved in the development of the model.
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Results
The model predicted that the use of stent-retriever thrombectomy in combination with IV t-
PA for the treatment of acute ischemic stroke was associated with improved patient outcomes
and lower overall costs compared with IV t-PA alone over the patient’s lifetime (Table 7).
The higher cost associated with the stent retriever was offset by the cost savings resulting
from lower long-term care costs due to improved patient outcomes, with an overall cost
saving of £33,190 per case. Higher QALYs and life years were observed in the stent retriever
+ IV t-PA arm (a difference of 2.31 and 1.81, respectively), reflecting the higher mortality
rate and lower quality of life in patients with more severe stroke outcomes. As stent retriever
+ IV t-PA led to greater health gains at a lower cost; it was dominant compared with IV t-PA
alone. The net monetary benefit (NMB) per case was £79,402 per QALY.
At one year, stent retriever + IV t-PA was demonstrated as being approximately cost-neutral,
with increased costs of £62 per patient compared with IV t-PA alone. At two years, stent
retriever + IV t-PA was associated with overall cost savings.
As stent retriever + IV t-PA was cost-saving, both the average cost per mRS score
avoided at 90 days and per additional independent patient at 90 days were negative values
(cost savings); -£33,486 and -£132,064 respectively. The costs saved due to improvement by
one mRS varied from £5,248 ($7,411) (moving from mRS 2 to mRS 1) and £111,209
(moving from mRS 3 to mRS 2). The cost savings associated with stent retriever + IV t-PA
were greatest in patients with higher functional dependence (mRS 3+). The full breakdown
by mRS can be found in Table 7.
Analysis of the components of the overall cost showed major differences in the long-
term care costs between treatment arms. The largest cost savings were observed post-
discharge, since stent retriever + IV t-PA was demonstrated to reduce the risk of long-term
disability compared with IV t-PA alone. The lifetime long-term care cost was £86,137 for
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patients who had received stent retriever + IV t-PA, compared with £123,057 for patients
who had received IV t-PA alone.
[BASE CASE RESULTS: TABLE 7]
Deterministic sensitivity analysis indicated that stent retriever + IV t-PA remained a
cost-effective treatment option across a large range of parameter values. The starting age,
health state utilities and long-term costs were the key drivers of the analysis, as indicated by
the tornado diagram in Figure 2a. A higher starting age, lower long-term costs and lower
health state utilities were associated with a lower net benefit.
A scenario analysis was undertaken, whereby it was assumed that patients entered a
rehabilitation phase after the acute phase, lasting from 90 days to one year, where they were
able to improve or deteriorate by one health state. In this scenario, stent retriever + IV t-PA
remained a dominant treatment option and was associated with cost savings of £28,134 and a
net benefit of £72,883, which while still favorable for stent-retriever thrombectomy, is less
cost-effective than in the base case analysis. Both treatment arms were associated with higher
QALYs and lower long-term costs than the base case analysis. A scenario where long-term
costs included in the model consisted only of hospital costs (i.e. nursing and residential costs
excluded) resulted in lower overall costs (cost saving of £894) and a lower net benefit of
£47,106.
[TORNADO DIAGRAM: FIGURE 2a]
Probabilistic sensitivity analysis indicated that the use of stent retriever + IV t-PA had
a 98.6% likelihood of cost-effectiveness compared with IV t-PA alone for a £20,000 per
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QALY threshold value, and a 99.0% likelihood of cost-effectiveness for a £30,000 threshold
value.
[SCATTERPLOT AND CEAC, FIGURES 2b and 2c]
Discussion
The objective of this analysis was to leverage clinical data specifically from SWIFT PRIME
trial to estimate the cost effectiveness of stent-retriever thrombectomy in the SWIFT PRIME
trial. The model predicted that the stent-retriever thrombectomy in combination with IV t-PA
for the treatment of patients with acute ischemic stroke due to proximal anterior intracranial
circulation occlusion was cost-saving with overall savings of £33,190 per treated patient
when compared with IV t-PA alone. The NMB was £79,402 per QALY. These results were
robust to a large range of parameters in the deterministic sensitivity analyses, and treatment
with stent retriever in combination with IV t-PA had a 98.6% probability of being cost-
effective at a threshold value of £20,000 per QALY in the probabilistic sensitivity analyses.
A main strength of the study was that the efficacy and adverse event data was based
on Phase III trial data from SWIFT PRIME13 - a randomized, open label, blinded outcome
observer trial that was stopped early due to strong evidence of efficacy combined stent-
retriever thrombectomy and IV t-PA. An additional strength was the inclusion of recurrent
stroke in the analysis to ensure that all clinical outcomes following a stroke were modelled as
well as the costs associated with them. Further, the model links health status by mRS to
patient outcomes of mortality, quality of life and resource use. Individual mRS scores, as
opposed to grouped health states of independent, dependent and dead, were also used for a
clearer breakdown on the patients’ pathway.
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We used key clinical data from the SWIFT PRIME study to evaluate the short-term costs and
health outcomes. However, the implications of stroke (in terms of cost, quality of life and
mortality) must be evaluated in the long-term to fully capture the relative benefits of
competing interventions. We therefore supplemented this approach with data from alternative
studies to predict costs and outcomes over a lifetime horizon, and although the absence of
long-term clinical data from SWIFT PRIME is a limitation of the analysis, the results suggest
that the model is robust to changes in the input parameters.
To date, only one other study has been conducted on the cost-effectiveness of the use
of stent retrievers in combination with IV t-PA therapy compared with IV t-PA alone. In this
study,18 an analysis in a US setting, intra-arterial therapy was associated with an ICER of
$14,137 (£10,011) and was estimated to have a probability of cost-effectiveness of 97.6% at a
threshold of $50,000 (£35,407). Using a £20,000 threshold, as used in this analysis, the
intervention would have a lower probability of cost-effectiveness. The Leppert study was
based on clinical efficacy data from MR CLEAN14, a clinical trial that utilized a variety of
endovascular therapies for acute ischemic stroke, including intra-arterial instillation of
fibrinolytic drugs, use of thromboaspiraton devices, coil retrievers, and stent retrievers that
had received a Conformité Européenne (CE) marking. Intra-arterial treatment in this study
was associated with lower clinical effectiveness than that observed in the SWIFT PRIME13
study, which focused exclusively on stent retrievers. The absolute between-group difference
in the proportion of patients who were functionally independent (mRS 0 to 2) at 90 days in
MR CLEAN was 13.5 percentage points in favor of the intervention group (32.6% vs.
19.1%), while in SWIFT PRIME the proportion of patients who were functionally
independent at 90 days was 25 percentage points in favor of the intervention group (60% vs.
35%). Mortality at 90 days did not differ significantly between groups in both trials; however,
the rate observed in the intervention group was higher in MR CLEAN compared to SWIFT
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PRIME, 21% vs. 9%, respectively. In addition to the different mechanical thrombectomy
devices utilized in these two trials, other factors such as differences in target patient
populations, differences in time to reperfusion and reperfusion rates achieved in the treatment
arms of both studies may have influenced the clinical effectiveness of mechanical
thrombectomy. Imaging criteria was less stringent in MR CLEAN, requiring evidence of
intracranial arterial occlusion only for inclusion of patients, while SWIFT PRIME also
required evaluation of ischemic core size/salvageable area via perfusion imaging/ASPECTS.
Eighty-seven percent of patients in the interventional arm of MR CLEAN received IV t-PA,
whereas SWIFT PRIME included only patients initially treated with IV t-PA. More
importantly, successful reperfusion (Thrombolysis in Cerebral Infarction (TICI) 2b-3 grade
flow) was achieved in 88% and 58.7% of patients in the intervention groups in SWIFT
PRIME and MR CLEAN, respectively. Time from stroke onset to reperfusion was also
longer in the MR CLEAN cohort vs. SWIFT PRIME cohort. Lastly, these studies were
carried out at different centers and thrombectomies were performed by different surgeons.
Collectively, these differences discussed above appear to have translated into differences in
clinical outcomes achieved across the studies. In addition, there was a significant difference
between the two studies in the utility values used. The utilities in the Leppert study were
derived from Samsa et al 199936 - a study that assessed patient preferences for hypothetical
major stroke using a patient survey, whilst utilities used in this study were derived from
patients with stroke identified as part of the Oxford Vascular study (OXVASC)32. Utilities
used in this study were higher than those reported by Samsa for the four health states
corresponding to mRS 0 to mRS 3. These differences in utilities are likely to have led to
improved cost-effectiveness within our study as the additional gains in quality of life in the
less severe health states will lead to improved QALY gains when patients move from mRS
levels of 4 or higher to mRS levels of 1-3. Another key difference between the two cost-
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effectiveness studies is in the acute and long-term costs used. The costs used in the Leppert
study were sourced from Earnshaw et al 200937 and Chamber et al 200238, and are reflective
of the US health care system. The costs were significantly lower in the Leppert study, which
will have contributed to the lower cost-effectiveness in that study.
A cost-effectiveness analysis of alteplase in the treatment of acute ischemic stroke
within 4.5 hours of symptom onset was undertaken for a NICE Single Technology Appraisal
in 2012, taking a UK healthcare perspective19. In this analysis, alteplase was found to have an
ICER of £2,441 per QALY when compared to no treatment (placebo). The life-time QALYs
gained by alteplase were 3.307 per patient, and the life-time cost of alteplase was £29,330 per
patient. Comparing these results to our analysis, stent-retriever thrombectomy in combination
with IV t-PA was dominant over a life-time time horizon when compared to IV t-PA alone.
The life-time QALYs gained by using the stent retriever were 7.01 and the life-time costs
associated with the stent retriever were £141,564. In addition to this, the life-time cost of IV
t-PA within our analysis was £183,897. This cost was substantially higher than that used
within the alteplase STA. This is likely to be a result of higher health-state cost inputs in our
analysis and a higher mortality observed within the alteplase model. Resource use costs used
within our analysis are more recent, dating from 2008-2009, compared to costs from 2001 in
the alteplase analysis. Because of this, the costs used within this analysis may be more
representative of the current patient pathway.
There are potential limitations of this study in relation to the resource use data used.
Both acute and long-term costs were taken from a study by Luengo-Fernandez et al.,25 which
is based on patients with atrial fibrillation with an average age of 80 years, followed between
2002 and 2007. As the patients are older than the SWIFT PRIME13 population, and also
suffer from atrial fibrillation, there may be additional comorbidities in this population and the
costs may not be representative of the cohort within our model. The estimates may also not
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be reflective of stroke care today. However, no other evidence is currently available, and the
costs were verified to be reasonable estimates by clinical opinion. Further research into the
costs of long term stroke care and the benefits of long term rehabilitation may be warranted
as it would have significantly reduced the uncertainty around estimated cost-effectiveness
estimates in the current model.
The economic aspect of this analysis focused only on the costs incurred to the NHS; a
societal perspective, incorporating the wider economic impact of improving stroke outcomes
(for example, by including the possibility of patients and their families returning to work)
would most likely improve the cost-effectiveness profile of the stent retriever still further.
One study concluded that the treatment of and productivity loss arising from stroke results in
total societal costs of £8.9 billion a year, with treatment costs accounting for approximately
5% of total UK NHS costs.7
Conclusion
Combined stent-retriever neurothrombectomy and IV t-PA is a highly effective treatment for
acute ischemic stroke and results in long term cost-saving when compared with IV t-PA
alone. These findings establish a strong case for introducing stent-retriever thrombectomy
into standard stroke care.
*Solitaire Revascularization Device is a registered trademark of Medtronic, Irvine, CA, USA
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